Targeted therapy for lung cancer: Beyond EGFR and ALK
M Herrera‐Juárez, C Serrano‐Gómez… - Cancer, 2023 - Wiley Online Library
Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …
Precision medicine in urothelial carcinoma: Current markers to guide treatment and promising future directions
EJ Miller, MD Galsky - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement The treatment landscape for urothelial cancer has changed dramatically
in the last 10 years, with the approval of several new treatments. At the same time, profiling …
in the last 10 years, with the approval of several new treatments. At the same time, profiling …
Evaluating Diff‐Quik cytology smears for large‐panel mutation testing in lung cancer—Predicting DNA content and success with low‐malignant‐cellularity samples
Background Cytology smears are commonly collected during endobronchial ultrasound–
guided transbronchial needle aspiration (EBUS TBNA) procedures but are rarely used for …
guided transbronchial needle aspiration (EBUS TBNA) procedures but are rarely used for …
Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer
N Wu, W Ge, RGW Quek, M Gleeson, JF Pouliot… - Future …, 2022 - Taylor & Francis
Background: Trends/outcomes associated with National Comprehensive Cancer Network
(NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer …
(NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer …
The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer …
D Čerina, K Krpina, M Jakopović, N Dedić Plavetić… - Cancers, 2023 - mdpi.com
Simple Summary Precision medicine has reached its current peak in non-small cell lung
cancer (NSCLC), with a constantly growing number of predictive biomarkers and new …
cancer (NSCLC), with a constantly growing number of predictive biomarkers and new …
Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study
FJ Fintelmann, NA Martin, I Tahir, EM Quinn… - Respiratory …, 2023 - Springer
Background Molecular testing can detect actionable genomic alterations and tumor cell
surface proteins in patients with non–small cell lung cancer (NSCLC). However, utilization …
surface proteins in patients with non–small cell lung cancer (NSCLC). However, utilization …
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung …
IM Abbass, DM Sheinson, A Shah, A Gondos… - Journal of Managed …, 2024 - jmcp.org
BACKGROUND: Clinical practice guidelines recommend broad-panel genomic profiling to
identify actionable genomic alterations for patients with advanced non–small cell lung …
identify actionable genomic alterations for patients with advanced non–small cell lung …
Suitability of respiratory endoscopy for sampling malignant thoracic tumors for comprehensive genomic profiling
K Fujimoto, Y Matsumoto, T Imabayashi… - Cancer …, 2023 - Wiley Online Library
Comprehensive genomic profiling (CGP) is implemented to detect actionable gene
aberrations and design matched therapies. Although malignant thoracic tumors are …
aberrations and design matched therapies. Although malignant thoracic tumors are …
Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests
K Miura, T Shukuya, R Greenstein, B Kaplan… - Journal of the National …, 2024 - jnccn.org
Background: Some genomic alterations in non–small cell lung cancer (NSCLC) are known
to differ according to race, sex, or age. These studies have been limited in sample size and …
to differ according to race, sex, or age. These studies have been limited in sample size and …
Real-world treatment patterns and outcomes of first-line immunotherapy among patients with advanced nonsquamous Nsclc harboring Braf, Met, or Her2 alterations
Introduction Data on utilization and clinical outcomes of programmed cell death protein or
programmed death-ligand 1 (PD-[L] 1) inhibitors in NSCLC with uncommon oncogenic …
programmed death-ligand 1 (PD-[L] 1) inhibitors in NSCLC with uncommon oncogenic …